Bioprocessing advancements are driving efficiency and scalability in drug manufacturing, particularly for complex modalities such as cell and gene therapies. Industry leaders emphasize the integration of automation, digital infrastructure, and AI-driven quality controls to reduce costs and production times. New manufacturing hubs, like Gilead Sciences’ recently broken ground facility, embody this trend, positioning companies to accelerate delivery of next-generation biologics and improve global therapeutic access.